RNA splicing: Disease and therapy

Briefings in Functional Genomics

Volumn 10, Issue 3, 2011, Pages 151-164

  Douglas, Andrew G L ^a   Wood, Matthew J A ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOMERVILLE COLLEGE   (United Kingdom)

Author keywords

Alternative splicing; Antisense oligonucleotides; DMD; RNA splicing; Splice correction; Splicing mutations

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ISOPROTEIN; MESSENGER RNA; RNA PRECURSOR;

ALTERNATIVE RNA SPLICING; ANTISENSE THERAPY; ARTICLE; DYSAUTONOMIA; EXON; GENE MUTATION; GENE TARGETING; HUMAN; MENKES SYNDROME; MYOTONIC DYSTROPHY; NEOPLASM; NONHUMAN; PROGERIA; RNA SPLICING; SPINAL MUSCULAR ATROPHY; GENERAL ASPECTS OF DISEASE; GENETICS; METABOLISM; MUTATION; REVIEW;

ALTERNATIVE SPLICING; DISEASE; DYSAUTONOMIA, FAMILIAL; EXONS; HUMANS; MUTATION; PROGERIA; RNA PRECURSORS; RNA, MESSENGER;

EID: 80054793884     PISSN: 20412649     EISSN: 20412657     Source Type: Journal    
DOI: 10.1093/bfgp/elr020     Document Type: Article

References (101)

1. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell, 5th edn. New York: Garland Science, 2008.
2. Ward AJ, Cooper TA. The pathobiology of splicing. J Pathol 2010;220:152-63.
3. Tazi J, Bakkour N, Stamm S. Alternative splicing and disease. Biochim Biophys Acta 2009;1792:14-26.
4. Blencoe BJ. Alternative splicing: new insights from global analyses. Cell 2006;126:37-47.
5. Romero PR, Zaidi S, Fang YY, et al. Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. Proc Natl Acad SciUSA 2006;103:8390-5.
6. Kanopka A, Mühlemann O, Akusjärvi G. Inhibition by SR proteins of splicing of a regulated adenovirus pre-mRNA. Nature 1996;381:535-8.
7. Martinez-Conteras R, Fisette JF, Nasim FU, et al. Intronic binding sites for hnRNP A/B and hnRNP F/H proteins stimulate pre-mRNA splicing. PLoS Biol 2006;4:e21.
8. Hertel KJ. Combinatorial control of exon recognition. JBiol Chem 2008;283:1211-5.
9. Luco RF, Allo M, Schor IE, et al. Epigenetics in alternative splicing. Cell 2011;144:16-26.
10. Tardiff DF, Lacadie SA, Rosbash M. A genome-wide analysis indicates that yeast pre-mRNA splicing is predominantly posttranscriptional. Mol Cell 2006;24:917-29.
11. Kornblihtt AR. Promoter usage and alternative splicing. Curr Opin Cell Biol 2005;17:262-8.
12. Gunderson FQ, Johnson TL. Acetylation by the transcriptional coactivator Gcn5 plays a novel role in co-transcriptional spliceosome assembly. PLoS Genet 2009; 5:e1000682.
13. Tilgner H, Nikolaou C, Althammer S, et al. Nucleosome positioning as a determinant of exon recognition. Nat Struct Mol Biol 2009;16:996-1001.
14. Spies N, Nielsen CB, Padgett RA, et al. Biased chromatin signatures around polyadenylation sites and exons. Mol Cell 2009;36:245-54.
15. Buratti E, Baralle FE. Influence of RNA secondary structure on the pre-mRNA splicing process. Mol Cell Biol 2004;24: 10505-14.
16. Muro AF, Caputi M, Pariyarath R, et al. Reulation of fibronectin EDA exon alternative splicing: possible role of RNA secondary structure for enhancer display. Mol Cell Biol 1999; 19:2657-71.
17. Kishore S, Stamm S. The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 2006; 311:230-2.
18. Sahoo T, del Gaudio D, German JR, et al. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucleolar RNA cluster. Nat Genet 2008;40: 719-21.
19. Watkins NJ, Lemm I, Luhrmann R. Involvement of nuclear import and export factors in U8 box C/D snoRNP biogenesis. Mol Cell Biol 2007;27:7018-27.
20. Liu S, Li P, Dybkov O, et al. Binding of the human Prp31 Nop domain to a composite RNA-protein platform in U4 snRNP. Science 2007;316:115-20.
21. Stamm S. Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Ml Genet 2002;11:2409-16.
22. Xiao SH, Manley JL. Phosphorylation of the ASF/SF2 RS domain affects both protein-protein and protein-RNA interactions and is necessary for splicing. Genes Dev 1997; 11:334-44.
23. Cardinali B, Cohen PT, Lamond AI. Protein phosphatase 1 can modulate alternative 50 splice site selection in a HeLa splicing extract. FEBS Lett 1994;352:276-80.
24. Amara SG, Jonas V, Rosenfeld MG, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982;298: 240-4.
25. Kornblihtt AR, Umezawa K, Vibe-Pedersen K, et al. Primary structure of human fibronectin: differential splicing may generate at least 10 polypeptides from a single gene. EMBOJ 1985;4:1755-9.
26. Zhang XH, Arias MA, Ke S, etal. Splicing of designer exons reveals unexpected complexity in pre-mRNA splicing. RNA 2009;15:367-76.
27. Dhir A, Buratti E. Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies. FEBSJ 2010;841-55.
28. Sun H, Chasin LA. Multiple splicing defects in an intronic false exon. Mol Cell Biol 2000;20:6414-25.
29. Sironi M, Menozzi G, Riva L, et al. Silencer elements as possible inhibitors of pseudoexon splicing. Nucleic Acids Res 2004;32:1783-91.
30. Zhang XH, Chasin LA. Computational definition of sequence motifs governing constitutive exon splicing. Genes Dev 2004;18:1241-50.
31. Pan Q, Shai O, Lee LJ, et al. Deep surveying of alternative splicing complexity in the human transcriptome by highthroughput sequencing. Nat Genet 2008;40:1413-5.
32. Krawczak M, Thomas NS, Hundrieser B, et al. Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing. HumMutat 2007;28:150-8.
33. Lopez-Bigas N, Audit B, Ouzouis C, et al. Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 2005;579:1900-3.
34. Slaugenhaupt SA, Blumenfeld A, Gill SP, et al. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet 2001;68:598-605.
35. Cheishvili D, Maayan C, Smith Y, et al. IKAP/hELP1 deficiency in the cerebrum of familial dysautonomia patients results in down regulation of genes involved in oligodendrocyte differentiation and in myelination. Hum Mol Genet 2007;16:2097-104.
36. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008;371:2120-33.
37. Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 1999;8:1177-83.
38. Kashima T, Rao N, David CJ, et al. hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. Hum Mol Genet 2007;16:3149-59.
39. Cartegni L, Hastings ML, Calarco JA, et al. Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. Am J Hum Genet 2006;78:63-77.
40. Nielsen KB, Sorensen S, Cartegni L, et al. Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am J Hum Genet 2007; 80:416-32.
41. Hennekam RC. Hutchinson-Gilford progeria syndrome: review of the phenotype. Am J Med Genet A 2006;140: 2603-24.
42. Pollard TD, Earnshaw WC. Cell Biology, 2nd edn. Philadelphia: Elsevier Inc., 2008.
43. Eriksson M, Brown WT, Gordon LB, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003;423:293-8.
44. de Bie P, Muller P, Wijmenga C, et al. Molecular pathogenesis of WIlson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes. J Med Genet 2007;44:673-88.
45. Moller LB, Tumer Z, Lund C, et al. Similar splice-site mutations of the ATP7A gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome. AmJ Hum Genet 2000;66:1211-20.
46. Liu F, Gong CX. Tau exon 10 alternative splicing and tauopathies. Mol Neurodegener 2008;3:8.
47. Glatz DC, Rujescu D, Tang Y, etal. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J Neurochem 2006;96:635-44.
48. Mahadevan M, Tsilfidis C, Sabourin L, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 30 untranslated region of the gene. Science 1992;255:1253-55.
49. Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001;293:864-7.
50. Lin X, Miller JW, Mankodi A, et al. Failure of MBNL1-dependetn post-natal splicing transitions in myotonic dystrophy. HumMol Genet 2006;15:2087-97.
51. Kuyumcu-Martinez NM, Wang GS, Cooper TA. Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 2007;28:68-78.
52. Charlet BN, Savkur RS, Singh G, et al. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002;10:45-53.
53. Zhang Z, Lotti F, Dittmar K, et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 2008;133:585-600.
54. WIlkie SE, Vaclavik V, Wu H, et al. Disease mechanism for retinitis pigmentosa (RP11) caused by missense mutations in the splicing factor gene PRPF31. MolVis 2008;14:683-690.
55. Vithana EN, Abu-Safieh L, Allen MJ, et al. A human homolog of yeast pre-mRNA splicing gene, PRP31, underlies autosomal dominant retinitis pigmentosa on chromosome 19q13.4 (RP11). Mol Cell 2001;8:375-81.
56. Boon KL, Grainger RJ, Ehsani P, et al. Prp8 mutations that cause human retinitis pigmentosa lead to a U5 snRNP maturation defect in yeast. Nat Struct Mol Biol 2007;14:1077-83.
57. Buratti E, Dork T, Zuccato E, et al. Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 2001;20:1774-84.
58. Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351:602-11.
59. Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314: 130-3.
60. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319:1668-72.
61. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutations in the FUS/LS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323:1205-8.
62. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 2007;39: 1432-49.
63. Benzeno S, Narla G, Allina J, et al. Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res 2004;64: 3885-91.
64. Narla G, DiFeo A, Yao S, et al. Targeted inhibition of the KLF6 splice variant, KLF6-SV1, suppresses prostate cancer cell growth and spread. Cancer Res 2005;65:5761-8.
65. Narla G, DiFeo A, Reeves HL, et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 2005;65:1213-22.
66. Narla G, DiFeo A, Fernandez Y, et al. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. JClin Invest 2008;118:2711-21.
67. Petronzelli F, Sollima D, Coppola G, et al. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. Genes Chrom Can 2001;31:398-401.
68. Chen LL, Sabripour M, Wu EF, et al. A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors. Oncogene 2005;24:4271-80.
69. Akgul C, Moulding DA, Edwards SW. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 2004;61: 2189-99.
70. Ghigna C, Giordano S, Shen H, et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 2005;20:881-90.
71. Karni R, de Stanchina E, Lowe SW, et al. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat StructMol Biol 2007;14:185-93.
72. Stamm S. Regulation of alternative splicing by reversible protein phosphorylation. J BiolChem 2008;283:1223-7.
73. Sumanasekera C, Watt DS, Stamm S. Substances that can change alternative splice-site selection. Biochem Soc Tran 2008;36:483-90.
74. Warf MB, Nakamori M, Matthys CM, et al. Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci USA 2009;106:18551-6.
75. Aartsma-Rus A, van Ommen GJ. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 2007;13:1609-24.
76. Manzur AY, Kinali M, Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child 2008;93:986-90.
77. Wood MJA, Gait MJ, Yin H. RNA-targeted splice correction therapy for neuromuscular disease. Brain 2010;133: 957-72.
78. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357:2677-86.
79. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009;8:918-28.
80. Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 1993;90:8673-7.
81. Sierakowska H, Sambade MJ, Agrawal S, et al. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc Natl Acad Sci USA 1996; 93:12840-4.
82. Friedman KJ, Kole J, Cohn JA, et al. Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem 1999;274:36193-9.
83. Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010;24:1634-44.
84. Passini MA, Bu J, Richards AM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011; 3:72ra18.
85. Gorman L, Suter D, Emerick V, et al. Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs. ProcNatl Acad SciUSA 1998;95:4929-34.
86. Vega AI, Perez-Cerda C, Desviat LR, et al. Functional analysis of three splicing mutations identified in the PMM2 gene: toward a new therapy for congenital disorder of glycosylation type Ia. HumMutat 2009;30:795-803.
87. Davis RL, Homer VM, George PM, et al. A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment. Hum Mutat 2009;30: 221-7.
88. Wheeler TM, Sobczak K, Lueck JD, et al. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 2009;325:336-9.
89. Skordis LA, Dunckley MG, Yue B, et al. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. ProcNatl Acad SciUSA 2003;100:4114-9.
90. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003;10:120-5.
91. Mansfield SG, Choa H, Walsh CE. RNA repair using spliceosome-mediated RNA trans-splicing. Trends Mol Med 2004;10:263-8.
92. Liu X, Jiang Q, Mansfield SG, et al. Partial correction of endogenous ΔF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol 2002;20:47-52.
93. Chao H, Mansfield SG, Bartel RC, et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. NatMed 2003;9:1015-9.
94. Coady TH, Lorson CL. Trans-splicing mediated improvement in a severe mouse model of spinal muscular atrophy. JNeurosci 2010;30:126-30.
95. Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors. MolTher 2009;17:767-77.
96. Zhu L, Mahato RI. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv 2010;7: 1209-26.
97. Song YK, Liu F, Chu S, et al. Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Hum GeneTher 1997;8:1585-94.
98. Hassane FS, Saleh AF, Abes R, et al. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. CellMol Life Sci 2010;67:715-26.
99. Yin H, Moulton HM, Betts C, et al. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 2009;18:4405-14.
100. Ivanova GD, Arzumanov A, Abes R, et al. Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 2008;36:6418-28.
101. Hallegger M, Llorian M, Smith CWJ. Alternative splicing: global insights. FEBSJ 2010;277:856-66.